Scancell (LON:SCLP) Sets New 12-Month High – Still a Buy?

Scancell Holdings plc (LON:SCLP)’s stock price reached a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 14 and last traded at GBX 13.39, with a volume of 1346237 shares. The stock had previously closed at GBX 13.50.

Scancell Stock Performance

The stock has a market capitalization of £138.96 million, a PE ratio of -24.35 and a beta of 0.35. The business’s fifty day moving average is GBX 12.10 and its two-hundred day moving average is GBX 10.61. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79.

Scancell (LON:SCLP) last posted its earnings results on Thursday, January 29th. The company reported GBX (0.55) earnings per share for the quarter. As a group, research analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.